FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386021791> ?p ?o ?g. }

• W4386021791 endingPage "S29" @default.
• W4386021791 startingPage "S28" @default.
• W4386021791 abstract "BACKGROUND CONTEXT Dexamethasone is widely used in postoperative spine patients, and there are few studies investigating the effects in a diabetic population that is more at risk when receiving the medication. PURPOSE This study aims to determine the effects of dexamethasone on postoperative complications in diabetic patients undergoing 1- or 2-level lumbar fusions. STUDY DESIGN/SETTING This is a retrospective study of the PearlDiver database. PATIENT SAMPLE A total of 7,865 patients were analyzed for this study. Of these, 715 patients in the test group (female=372, male=343) received dexamethasone postoperatively. A total of 7,150 patients who did not receive dexamethasone were propensity-matched and included in the control group. OUTCOME MEASURES Medical complications including DVT, UTI, AKI, pneumonia, and transfusion were assessed at 90 days. Surgical site and instrumentation complications were assessed at 30 days, 90 days, and 1 year. METHODS Patients undergoing 1- or 2-level posterior lumbar fusions with a diagnosis of diabetes mellitus who received dexamethasone within three days postoperatively were identified using the PearlDiver database. Patients were propensity-matched in a 1:10 ratio to diabetic patients undergoing the same procedure who did not receive dexamethasone. Medical complications including DVT, UTI, AKI, pneumonia, and transfusion were assessed at 90 days. Surgical site and instrumentation complications were assessed at 30 days, 90 days, and 1 year. RESULTS A total of 7,865 patients comprise the basis of this analysis and were included in this study. 715 patients in the test group (female=372, male=343) received dexamethasone postoperatively. A total of 7,150 patients who did not receive dexamethasone were included in the control group. Patients in the test group had a significantly higher risk of DVT at 90 days (OR: 1.9 [1.2-3.0], p= 0.0068). There was no difference in UTI, AKI, pneumonia, or transfusion at 90 days (p>0.05). Surgical site complications were significantly elevated in the test group at 30 days (OR: 1.51 [1.01-2.13], p=0.019), 90 days (OR: 1.38 [1.00-1.91], p=0.047), and 1 year (OR: 1.36 [1.01-1.84], p=0.046). Instrumentation complications were also significantly elevated in the test group at all time points: 30 day (OR: 2.0 [1.16-3.43], p=0.012), 90 day (OR: 2.18 [1.45-3.28], p=0.0002), 1 year (OR: 1.63 [1.22-2.19], p=0.001). Length of stay was shorter in the test group, 3.29 days vs 3.48 days respectively (p= 0.0259). CONCLUSIONS Administration of dexamethasone in the postoperative period after lumbar fusion is associated with higher risk of surgical site and instrumentation complications at 30 days, 90 days, and 1 year in patients undergoing elective one- or two-level lumbar fusions. Dexamethasone, widely used in the management of postoperative spinal fusion, is associated with increased risk of surgical site and instrumentation complications in diabetic patients, which should be considered before administration. FDA Device/Drug Status This abstract does not discuss or include any applicable devices or drugs. Dexamethasone is widely used in postoperative spine patients, and there are few studies investigating the effects in a diabetic population that is more at risk when receiving the medication. This study aims to determine the effects of dexamethasone on postoperative complications in diabetic patients undergoing 1- or 2-level lumbar fusions. This is a retrospective study of the PearlDiver database. A total of 7,865 patients were analyzed for this study. Of these, 715 patients in the test group (female=372, male=343) received dexamethasone postoperatively. A total of 7,150 patients who did not receive dexamethasone were propensity-matched and included in the control group. Medical complications including DVT, UTI, AKI, pneumonia, and transfusion were assessed at 90 days. Surgical site and instrumentation complications were assessed at 30 days, 90 days, and 1 year. Patients undergoing 1- or 2-level posterior lumbar fusions with a diagnosis of diabetes mellitus who received dexamethasone within three days postoperatively were identified using the PearlDiver database. Patients were propensity-matched in a 1:10 ratio to diabetic patients undergoing the same procedure who did not receive dexamethasone. Medical complications including DVT, UTI, AKI, pneumonia, and transfusion were assessed at 90 days. Surgical site and instrumentation complications were assessed at 30 days, 90 days, and 1 year. A total of 7,865 patients comprise the basis of this analysis and were included in this study. 715 patients in the test group (female=372, male=343) received dexamethasone postoperatively. A total of 7,150 patients who did not receive dexamethasone were included in the control group. Patients in the test group had a significantly higher risk of DVT at 90 days (OR: 1.9 [1.2-3.0], p= 0.0068). There was no difference in UTI, AKI, pneumonia, or transfusion at 90 days (p>0.05). Surgical site complications were significantly elevated in the test group at 30 days (OR: 1.51 [1.01-2.13], p=0.019), 90 days (OR: 1.38 [1.00-1.91], p=0.047), and 1 year (OR: 1.36 [1.01-1.84], p=0.046). Instrumentation complications were also significantly elevated in the test group at all time points: 30 day (OR: 2.0 [1.16-3.43], p=0.012), 90 day (OR: 2.18 [1.45-3.28], p=0.0002), 1 year (OR: 1.63 [1.22-2.19], p=0.001). Length of stay was shorter in the test group, 3.29 days vs 3.48 days respectively (p= 0.0259). Administration of dexamethasone in the postoperative period after lumbar fusion is associated with higher risk of surgical site and instrumentation complications at 30 days, 90 days, and 1 year in patients undergoing elective one- or two-level lumbar fusions. Dexamethasone, widely used in the management of postoperative spinal fusion, is associated with increased risk of surgical site and instrumentation complications in diabetic patients, which should be considered before administration." @default.
• W4386021791 created "2023-08-22" @default.
• W4386021791 creator A5018135534 @default.
• W4386021791 creator A5023248680 @default.
• W4386021791 creator A5047831340 @default.
• W4386021791 creator A5053101840 @default.
• W4386021791 creator A5090132968 @default.
• W4386021791 creator A5007647604 @default.
• W4386021791 date "2023-09-01" @default.
• W4386021791 modified "2023-10-09" @default.
• W4386021791 title "56. Use of dexamethasone in the immediate postoperative period is associated with increased risk of instrumentation and surgical site complications in diabetic patients undergoing lumbar spinal fusion" @default.
• W4386021791 doi "https://doi.org/10.1016/j.spinee.2023.06.108" @default.
• W4386021791 hasPublicationYear "2023" @default.
• W4386021791 type Work @default.
• W4386021791 citedByCount "0" @default.
• W4386021791 crossrefType "journal-article" @default.
• W4386021791 hasAuthorship W4386021791A5007647604 @default.
• W4386021791 hasAuthorship W4386021791A5018135534 @default.
• W4386021791 hasAuthorship W4386021791A5023248680 @default.
• W4386021791 hasAuthorship W4386021791A5047831340 @default.
• W4386021791 hasAuthorship W4386021791A5053101840 @default.
• W4386021791 hasAuthorship W4386021791A5090132968 @default.
• W4386021791 hasConcept C126322002 @default.
• W4386021791 hasConcept C134018914 @default.
• W4386021791 hasConcept C141071460 @default.
• W4386021791 hasConcept C151730666 @default.
• W4386021791 hasConcept C2779343474 @default.
• W4386021791 hasConcept C2780401358 @default.
• W4386021791 hasConcept C44575665 @default.
• W4386021791 hasConcept C555293320 @default.
• W4386021791 hasConcept C71924100 @default.
• W4386021791 hasConcept C86803240 @default.
• W4386021791 hasConceptScore W4386021791C126322002 @default.
• W4386021791 hasConceptScore W4386021791C134018914 @default.
• W4386021791 hasConceptScore W4386021791C141071460 @default.
• W4386021791 hasConceptScore W4386021791C151730666 @default.
• W4386021791 hasConceptScore W4386021791C2779343474 @default.
• W4386021791 hasConceptScore W4386021791C2780401358 @default.
• W4386021791 hasConceptScore W4386021791C44575665 @default.
• W4386021791 hasConceptScore W4386021791C555293320 @default.
• W4386021791 hasConceptScore W4386021791C71924100 @default.
• W4386021791 hasConceptScore W4386021791C86803240 @default.
• W4386021791 hasIssue "9" @default.
• W4386021791 hasLocation W43860217911 @default.
• W4386021791 hasOpenAccess W4386021791 @default.
• W4386021791 hasPrimaryLocation W43860217911 @default.
• W4386021791 hasRelatedWork W1982434602 @default.
• W4386021791 hasRelatedWork W2094844283 @default.
• W4386021791 hasRelatedWork W2354241142 @default.
• W4386021791 hasRelatedWork W2365729717 @default.
• W4386021791 hasRelatedWork W2372664423 @default.
• W4386021791 hasRelatedWork W2387893491 @default.
• W4386021791 hasRelatedWork W2388510727 @default.
• W4386021791 hasRelatedWork W2944534848 @default.
• W4386021791 hasRelatedWork W2966285610 @default.
• W4386021791 hasRelatedWork W3029340634 @default.
• W4386021791 hasVolume "23" @default.
• W4386021791 isParatext "false" @default.
• W4386021791 isRetracted "false" @default.
• W4386021791 workType "article" @default.